Allogene Therapeutics (ALLO) Asset Utilization Ratio (2021 - 2026)

Allogene Therapeutics has reported Asset Utilization Ratio for 4 years, with the latest figure at 0.0 in Q4 2024.

• Quarterly Asset Utilization Ratio fell 72.4% year-over-year to 0.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.0 (down 72.4% YoY) and the FY2024 annual result came in at 0.0, down 71.54% from the prior year.
• Asset Utilization Ratio retreated to 0.0 in Q4 2024 per ALLO's latest filing, from 0.0 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.11 in Q4 2021 and troughed at 0.0 in Q4 2024.
• A 4-year average of 0.03 and a median of 0.0 in 2023 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio soared 135.45% in 2022, then slumped 99.84% in 2023.
• Over 4 years, Asset Utilization Ratio stood at 0.11 in 2021, then sank by 99.83% to 0.0 in 2022, then slipped by 22.95% to 0.0 in 2023, then slumped by 72.4% to 0.0 in 2024.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.